Generic Name and Formulations:
Bupivacaine HCl 2.5mg/mL, 5mg/mL, 7.5mg/mL; soln for inj.
Indications for MARCAINE:
Production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures (0.25% and 0.5% only).
See literature for recommended dosages based on procedures. Epidural anesthesia: administer test dose first; monitor for CNS or cardiovascular toxicity. 0.25% soln when used for caudal, epidural, or peripheral nerve block, produces incomplete motor block. Should be used for operations in which muscle relaxation is not important, or when another means of providing muscle relaxation is used concurrently. Onset of action may be slower than with the 0.5% or 0.75% solns. 0.5% soln provides motor blockade for caudal, epidural, or nerve block, but muscle relaxation may be inadequate for operations in which complete muscle relaxation is essential. 0.75% soln produces complete motor block. Most useful for epidural block in abdominal operations requiring complete muscle relaxation, and for retrobulbar anesthesia. Not for obstetrical anesthesia. For most indications, a single dose is sufficient. Max 400mg/day. Debilitated, elderly, acutely ill: reduce dose.
Obstetrical paracervical block.
0.75% concentration not recommended for obstetrical anesthesia: cardiac arrest with difficult resuscitation or death has occurred. To be administered under the supervision of experienced clinicians. Have intubation, artificial respiration, oxygen therapy and reversal agents available. Solns containing antimicrobial preservatives: do not use for epidural or caudal anesthesia. IV regional anesthesia (Bier Block): not recommended. Cardiovascular disease. Hepatic or renal impairment. Monitor cardiovascular and respiratory vital signs. Malignant hyperthermia. Head and neck administration. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Epinephrine: concomitant ergot-type oxytocic drugs not recommended; severe persistent hypertension may occur. Caution with MAOIs, triptyline and imipramine type antidepressants; avoid. Phenothiazines, butyrophenones may reduce or reverse pressor effect of epinephrine.
CNS effects (eg, excitation, depression, restlessness, anxiety, dizziness, tremors), cardiovascular effects (eg, myocardium depression, decreased cardiac output, heart block, hypotension, bradycardia, ventricular arrhythmias, cardiac arrest), allergic-type reactions, neurologic effects (eg, spinal block, urinary retention, paresthesia, weakness, headache, paralysis of lower extremities).
Marcaine: Single-dose vials (10mL, 30mL)—10; Multi-dose vials 0.25%, 0.5% (50mL)—1 (contains methylparaben). Marcaine with epinephrine: Single-dose vials (10mL, 30mL)—10; Single-dose ampuls 0.5% (3mL)—10; Multi-dose vials (50mL)—1 (contains sodium metabisulfite)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML